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Abstract  Peritoneal  carcinomatosis  refers  to  a  shedding  or  tumor  that  spreads  to  the  periton-
eal serosa  and  structures  of  the  abdominal  cavity.  It  is  an  entity  with  a  poor  prognosis.  Several
conditions  can  cause  this,  the  most  common  being  colon,  rectum,  ovary,  stomach  or  appendix
cancers,  including  peritoneal  pseudomyxoma,  among  others.  The  abdominal  cavity  invasion  is
considered  a  clinical  stage  IV.  For  a  long  time  life  expectancy  of  this  entity  was  very  short.  With
the advent  of  meticulous  techniques  in  cytoreductive  surgery  (CRS)  and  hyperthermic  intraperi-
toneal chemotherapy  (HIPEC)  the  prognosis  of  patients  has  changed.  In  some  conditions,  these
procedures  are  standard  treatments.  CRS  is  a  very  important  prognostic  factor;  leaving  a  less
residual disease  in  the  patient,  the  evolution  will  be  better.  The  HIPEC  starts  immediately  after
the surgical  event.  The  hyperthermia  increases  the  cytotoxic  effect  of  antineoplastic  drugs.
Numerous  studies  have  appeared  in  medical  literature  wherein  the  clear  improvement  in  sur-
vival of  the  affected  population  is  demonstrated.  It  is  essential  that  a  multidisciplinary  team
participates  in  the  decision  for  the  best  treatment  option  and  the  maximum  clinical  beneﬁt  of
the patients.
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ing  them  a  number  (score  from  0  to  39).  PCI  has  a  prognosis
value  in  addition  to  estimating  the  possibility  of  full  cytore-
duction.  A  series  published  a  survival  rate  at  5  years  of
50%  for  PCI  <  10,  20%  for  PCI  10--20  and  0%  for  PCI  >  20.5,11,12
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Introduction
Peritoneal  carcinomatosis  (PC)  refers  to  the  shedding,
implantation  and  dissemination  of  a  tumor,  either  localized
or  massive,  to  the  peritoneal  serosa,  as  well  as  the  adjacent
structures  of  the  abdominal  cavity.  Its  presence  indicates
a  clinical  stage  IV.  It  is  usually  associated  with  gynecologi-
cal  tumors  and  tumors  of  the  digestive  tract.1--3 The  exact
incidence  of  PC  as  a  primary  site  and  as  a  recurrent  site
is  not  known  with  any  certainty,  since  most  analytic  and
imaging  studies  used  to  monitor  different  pathologies  do
not  allow  for  the  detection  of  said  dissemination  in  ini-
tial  studies.  Numbers  vary  according  to  the  pathology;  the
most  representative  is  colon  cancer.  Estimations  suggest
that  initial  recurrence  in  the  peritoneum  after  a  surgery
with  curative  intentions  is  10--20%.  Peritoneal  dissemination
occurs  in  40--70%  of  total  recurrences  and  only  5--8%  present
a  disease  strictly  conﬁned  in  the  peritoneum.  Considering
all  patients  with  the  inclusion  of  all  original  pathologies,
medical  literature  shows  that  15%  of  patients  arrive  with
PC  at  ﬁrst  and  35%  die  of  intraperitoneal  recurrence.4 Up
to  a  few  years  ago,  this  entity  had  had  an  adverse  prog-
nosis  with  a  fatal  outcome  within  months.5 However,  the
evolution  of  the  disease  can  be  changed  with  an  excel-
lent  full  cytoreductive  surgery  (CRS)  and  the  emergence  of
intraperitoneal  chemotherapy  (IPCT).  Life  expectancy  used
to  be  very  limited  and  dependant  on  the  base  pathology:
between  3  and  6  months  for  gastric  base  PC,4,6 11--21  months
for  colon/rectal  PC  and  14--24  months  for  ovarian  PC,  on
average.  The  variant  linked  to  peritoneal  pseudomyxoma
has  shown  better  survival  rates,  due  to  the  tumor’s  biology
and  its  response  to  multimodal  treatment.  In  all  the  previ-
ously  mentioned  cases,  CRS  and  IPCT  have  increased  these
numbers.
Today,  peritoneal  affection  is  being  considered  as  a
locoregional  dissemination,  thus  generating  the  idea  of
performing  metastasectomies  in  said  entity  with  the  pur-
pose  of  leaving  patients  disease-free.  In  the  late  80s,
Dr.  Sugarbaker  developed  a  treatment  with  a  radical
approach,  consisting  of  a  combination  of  CRS  and  IPCT,
the  latter  in  its  early  post-operative  modality  (EPIC  early
postoperative  intraperitoneal  chemotherapy),  and  in  cases
requiring  hyperthermia  (HIPEC  hypertermic  intraperitoneal
chemotherapy).  The  key  objective  of  the  radical  approach
is  to  completely  eliminate  the  visible  disease  through  CRS
and  EPIC  or  HIPEC,  and  to  eradicate  non-visible  tumor
residues.  CRS  ought  to  be  thorough  in  order  to  release  adher-
ences,  in  addition  to  retreating  tumor  implantations,  so  that
chemotherapy,  once  administered,  is  distributed  homoge-
neously  amongst  the  intra-abdominal  organ  surfaces.7,8
During  the  last  decades,  CTIP  and  CRS  have  been  sig-
niﬁcantly  revolutionized,  thus  resulting  in  favorable  results
in  patient  survival  rates,  which  had  not  been  achievable  in
previous  years.
Physiopathology and the plasmatic peritoneal
barrierCancers  in  the  abdomen  spread  via  three  different  routes:
haematogeneous,  lymphatic  and  celomic.  The  latter  led  to
the  hypothesis  that  in  eliminating  this  type  of  dissemination,
F
itosis  99
he  risk  of  extension  of  the  disease  would  decrease  and
ree-of-recurrence  survival  rate  would  increase.  Periton-
al  liquid  goes  from  the  pelvis  to  the  diaphragm  and  is
eﬁned  by  the  reﬂections  of  the  peritoneum.  Intraperi-
oneal  seeding  through  ascites  is  one  of  the  most  signiﬁcant
orms  of  peritoneal  metastasis  and  the  leading  cause  of
C.  Regardless  of  the  dissemination  mechanism,  tumor  cells
preading  to  the  peritoneal  cavity  do  so  in  different  ways:
hrough  gravity,  peristalsis  and/or  negative  pressure  of  the
iaphragmatic  muscles.2,9 Once  the  tumor  cells  adhere,  they
enetrate  the  mesothelial  monolayer  and  initiate  the  PC
rocess.  The  peritoneal  tissue  provides  a  source  that  is  rich
n  nutrients,  growth  factors  and  chemokines,  leading  to  a
avorable  environment  for  tumor  cell  proliferation.9 The
lasmatic  peritoneal  barrier  maintains  a  positive  gradient
f  chemotherapy,  causing  medications  with  a  high  molecular
eight  to  remain  in  the  abdominal  cavity  for  a  longer  period
f  time,  allowing  for  a  greater  exposure  of  tumor  cells  to  the
edications,  compared  to  the  intravenous  route.1,4,10
iagnosis
ifferent  techniques  are  used  in  diagnosis,  such  as  imaging
tudies  like  ultrasounds,  CAT  scans,  NMR  scans  and  PET/CT
ositron  emission  tomographies  with  ﬂuorodeoxyglucose 18F.
evertheless,  these  studies  have  their  limitations.  They  are
sually  used  more  in  staging  and  for  non-resectable  disease
ssessment.4 CAT  scan  sensitivity  for  PC  diagnosis  ranges
etween  41  and  93%  with  a  speciﬁcity  between  79  and
6%.  CAT  scans  can  prove  previously  established  imaging
atterns,  including  the  ‘‘omental  cake’’  which  represents
at  implants,  thickening  and  heterogeneity,  subcapsular
mplants,  nodular  lesions,  associates  and  mesenteric  fat  tis-
ue  tumor  inﬁltration.2
There  are  different  systems  to  measure  PC.  The  most  uti-
ized  is  the  peritoneal  carcinomatosis  index  (PCI),  which  is
ased  on  the  peritoneal  nodules’  size  and  quantitative  dis-
ribution.  The  abdominal  cavity  is  divided  into  13  regions
nd  the  volume  of  the  disease  is  determined  in  every  region
Fig.  1).  After  a  thorough  surgical  inspection,  the  extension
f  the  disease  is  measured  in  relation  to  every  region,  assign-PCI 12
igure  1  Abdominopelvic  regions.  Peritoneal  carcinomatosis
ndex.
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ugarbaker  recommends  a  palliative  management  with  a  PCI
reater  than  20.13 Some  groups  use  a  PCI  >  26  as  a  reference.
urgical treatment
he  decision  of  the  oncological  surgical  treatment  type
epends  on  the  anatomic  location  of  the  malignancy  as
ell  as  its  biological  behavior.  Cytoreductor  management
ay  require  6  types  of  peritonectomy  procedures,  used  to
esect  cancer  from  all  abdominal  surfaces.  These  are  the
ypes:  (1)  Pelvic  peritonectomy,  with  or  without  the  exci-
ion  of  the  sigmoid  colon  or  rectum,  mesorectum,  uterus
nd  annexes.  (2)  Major  omentectomy,  with  or  without  a
plenectomy,  and  with  or  without  a  right  colectomy.  (3)  Left
emidiaphragm  peritonectomy.  (4)  Right  hemidiaphragm
eritonectomy,  with  or  without  a  Glisson  capsule,  and  with
r  without  a  sub-hepatic  peritonectomy.  (5)  Minor  omentec-
omy  with  a  cholecystectomy,  and  (6)  Gastrectomy  and  other
ntestinal  resections.7 Major  omentectomy,  oophorectomy
in  post-menopausal)  as  well  as  cholecystectomy  will  always
e  carried  out,  the  latter  with  the  purpose  of  avoiding
ost-operative  complications  related  to  chemotherapy.  Peri-
onectomy  procedures  allow  us  to  accomplish  the  objective
f  removing  all  visible  disease,  with  acceptable  post-surgical
omplications,  reporting  morbidities  in  25%  and  mortality
n  1.5%.12 CRS  can  be  evaluated  using  the  Sugarbaker  tech-
ique,  according  to  the  residual  disease  classiﬁcation  after
ytoreductive  surgery:  CC0  deﬁned  as  non-visible,  CC1,  per-
istent  nodules  under  0.25,  CC2,  nodules  between  0.25  and
.5  cm  and  CC3,  nodules  over  2.5  cm.14 The  important  thing
s  to  accomplish  full  cytoreductive  surgery,  determined  as
C0  or  CC1.15,16 CRS  residual  disease  plays  a  prognosis  role
egarding  survival  rate.  At  5  years,  it  is  35%  with  CC0  and
C1  versus  0%  with  CC2  and  CC3.12 Recently  Esquivel,  et  al.
eported  the  role  of  laparoscopy  for  the  completion  of  CRE
ith  HIPEC  in  14  patients.  CC0  was  accomplished  in  13
atients,  10  (77%)  via  laparoscopy  and  3  (23%)  via  open
urgery.  However,  they  were  well-selected  patients,  with  a
ow  tumor  load  and  without  intestinal  involvement.17
TIP
s  its  name  states,  it  is  about  administrating  chemother-
py  agents  via  intraperitoneal.  There  is  evidence  that  some
rugs  administered  in  large  amounts  via  intraperitoneal
aintain  a  signiﬁcantly  higher  concentration  in  the  perit-
neal  area  compared  to  plasmatic  concentration.  A  large
oncentration  of  drugs  offers  a  biochemical  advantage  in  the
reatment  of  patients  with  microscopic  neoplastic  disease
n  the  peritoneal  cavity.18 Very  positive  results  with  the  use
f  chemotherapy  in  patients  with  peritoneal  carcinomato-
is,  sarcomatosis  and  mesothelioma  have  been  reported.
he  most  commonly  used  drugs  in  the  CTIP  scenario  are
xaliplatin,  irinotecan,  adriamycin,  cisplatin,  mitomycin,
aclitaxel  and  gemcitabine.  CTIP  causes  local  and  sys-
emic  toxicity,  since  the  drugs  will  eventually  enter  the
lood  stream.1 Once  the  drugs  are  administered  via  IP,  they
estroy  tumor  cells  directly,  as  well  as  decrease  cells  of  the
nﬂammatory  process,  altering  the  ability  to  withstand  an
nfectious  process.  Thus,  sterility  and  asepsis  during  the  full
rocedure  are  imperative.  As  previously  mentioned,  CTIP
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an  be  administered  in  two  different  ways,  EPIC  and  HIPEC,
oth  preceded  by  CRS.  The  difference  between  them  is  that
atheters  are  left  for  the  administration  of  CT  in  the  ﬁrst
ne,  which  is  usually  performed  in  5  days,  and  the  second
ne  is  a  single  postoperative  procedure.  Today,  the  most
tilized  is  HIPEC.  There  are  studies  where  both  HIPEC  and
PIC  treatment  modalities  are  combined,  which  has  not  gen-
rated  beneﬁts  in  survival  rates,  though  it  has  generated
reater  toxicity.19
IPEC
he  connection  between  chemotherapy  and  hyperthermia
s  what’s  known  as  HIPEC.  It  is  limited  to  a single  treat-
ent  session.  Simultaneous  use  of  HIPEC  with  intravenous
hemotherapy  (bidirectional  chemotherapy)  improves  sur-
ival  rate  results  in  some  types  of  PC.  The  interest  on
yperthermia  has  focused  on  three  fundamental  aspects:
1)  increased  temperatures  themselves  have  a  cytotoxic
ffect,  (2)  hyperthermia  increases  the  inactivation  by  radi-
tion  rate  and  more  importantly  (3)  the  cytotoxic  effect
f  chemotherapy  agents  is  increased  with  the  elevated
ocal  temperature.20 Hyperthermia  of  40--42 ◦C,  along  with
hemotherapy,  help  drugs  penetrate  malignant  tissue  (from
 to  6  mm),  thus  increasing  the  cytotoxic  effect.2,4 From  the
rst  studies  within  the  use  of  CTIP  literature,  is  phase  I,
hich  researched  the  role  of  5-ﬂuorouracil.  Said  drug  was
dministered  through  dialysis  catheters  to  individuals  with
umors  limited  to  the  peritoneal  cavity,  the  patients  devel-
ped  the  same  adverse  effects  caused  by  that  of  intravenous
dministration,  two  patients  displayed  a  clinical  response,
oncentrations  of  peritoneal  liquid  were  measured  and  they
ecreased  in  the  ﬁrst  order  with  an  average  lifespan  of  1.6  h.
n  4  h  82%  of  the  IP  drug  was  absorbed,  and  the  medication’s
lasmatic  levels  began  to  rise  after  30--45  min.  There  was
 signiﬁcant  difference  between  intraperitoneal  and  plas-
atic  levels;  concentrations  in  peritoneal  liquid  were  298
imes  greater  at  4  h  compared  to  the  levels  in  blood.21 In
he  late  80s,  Sugarbaker  proved  that  it  was  possible  to  keep
atients  with  pseudomyxoma  peritonei  free  of  disease  with
ytoreductive  surgery  and  the  administration  of  chemother-
py  with  5-ﬂuorouracil  and  mitomycin  C.22 Other  studies
ave  used  other  drugs  which  have  proven  to  be  compatible
ith  hyperthermia,  these  being  oxaliplatin,  mitomycin  C,
isplatin,  doxorubicin,  paclitaxel  and  irinotecan.23,24 Intra-
bdominal  temperature  should  not  exceed  43◦ in  order  to
void  adverse  effects  harmful  to  the  tissue,  such  as  intesti-
al  perforation.
atient selection for CTIP
n  the  past,  many  patients  were  treated  with  HIPEC  despite
eing  CC2  and  CC3,  resulting  in  the  absence  of  expected
eneﬁts.  Residual  disease  is  an  important  criterion  in  patient
election  for  this  management  protocol.  The  extent  of  the
isease  at  the  time  the  patient  begins  treatment  will  corre-
ate  to  the  eventual  results.  Patient  selection  should  be  done
arly,  and  it  is  important  to  have  a  multidisciplinary  team
articipating  in  the  process.  Today,  there  are  4  major  points
o  take  into  account  when  selecting  patients:  the  invasive
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Table  1  Indications  for  the  combined  treatment  of  CRS  and
CTIP.
1)  Malignant  ascites
2) Peritoneal  pseudomyxoma  after  a  CRS
3) Peritoneal  mesothelioma  after  a  CRS
4) Primary  colon  and  rectal  cancer
- Peritoneal  seeding  of  limited  distribution  and  small
volume
- Perforated  colon  cancer
- Colon  cancer  involving  adjacent  organs
- Colon  cancer  disseminated  to  the  ovaries
- Colon  cancer  with  a  positive  cytology  IP
- Tumor  rupture  at  a  primary  resection
5) Recurrent  colon  and  rectal  cancer  with  carcinomatosis
- Peritoneal  seeding  of  limited  distribution  and  small
volume
- Krukenberg
- Tumor  rupture  at  a  resection  of  a  recurrence
- Completed  ebulking  of  a  recurring  disease  at  more
than one  site
6)  Recurring  ovarian  cancer  with  limited  dissemination  to  the
peritoneum
- Prolonged  interval  free  of  disease  between  initial
treatment  and  recurrence
- Limited  or  no  options  for  chemotherapy  via  IV
7) Primary  gastric  cancer  with  limited  peritoneal  implants
after  a  complete  resection  of  both
8) Peritoneal  sarcomatosis
- Sarcomatosis  following  CRS
-  Primary  abdomino  pelvic  sarcomatosis  with  doubtful
resection  margins
- Primary  abdomino  pelvic  sarcomatosis  with  tumor
the  loops  removing  ﬁbrin  bridges  and  adherences,  place-
ment  of  administration  tubes  (at  least  a perfusion  tube)
and  drainage  tubes  takes  place  prior  to  HIPEC.  In  addition,
three  temperature  sensors  are  placed  in  the  abdominal  cav-
ity  (superior,  middle  and  inferior).  Before  initiating  HIPEC,
the  chemotherapy  complement  being  used  is  administered
intravenously  (bidirectional  chemotherapy).  There  are  two
techniques  to  perform  HIPEC;  open  (coliseum)  and  closed.
The  most  utilized  technique  is  coliseum  (Fig.  2).  There  are
no  studies  proving  that  one  is  better  than  the  other.  An  extra-
corporeal  circulation  machine  is  used  for  HIPEC  treatment
(Fig.  3),28 which  previously  heats  an  isotonic  dialysis  solution
or  a glucose  solution  at  1.5%,  minimum  of  2  l,  at  40--42 ◦C.
Once  the  temperature  is  reached,  the  abdominal  cavity  is
ﬁlled  with  the  previously  preheated  solution.  This  solution
is  distributed  evenly,  trying  to  reach  the  desired  tempera-
ture  homogenously  in  the  abdominal  cavity,  and  once  this
is  accomplished  the  administration  of  chemotherapy  takes
place,  manipulating  the  inﬂux  tube  as  well  as  the  tissue  and
intestinal  loops  in  order  to  continue  with  the  uniformity  of
intra-abdominal  temperature.  After  the  time,  which  can  be
between  30  and  120  min,  is  completed,  the  cavity  is  emp-
tied,  the  abdomen  is  reassessed  in  order  to  ﬁnd  tissue  lesions
or  bleeding  and  when  the  procedure  is  ﬁnished,  the  circuitrupture  at  resection
nature  of  the  disease,  previous  CATs,  ICPs  and  the  full  CRS
score.2,25
Indications  for  CRS  and  CTIP  are  shown  in  Table  1.
Patients  with  a  good  functional  state,  a  low  volume  perit-
oneal  disease  and  an  absence  of  extra-abdominal  metastasis
are  more  commonly  beneﬁted  by  the  treatment.1,26 Patients
admitted  to  CRS  and  HIPEC  must  have  a  leukocyte  count
of  >3000/mm3,  polymorphonuclears  of  >1500,  platelet
count  of  >100,000/mm3,  normal  creatinine  or  calculated
depuration  at  >50  ml/min  and  a  signed  consent  form.27
Contraindications  for  HIPEC  are  age  >70  years,  major  comor-
bidities,  a  reaction  to  chemotherapeutics,  malnutrition,
extra-abdominal  metastasis,  non-rescuable  hepatic  metas-
tasis,  massive  retroperitoneal  disease  or  voluminous  lymph
node  involvement  and  signs  of  intestinal  occlusion.4 Con-
cerning  sarcomatosis  treatment  by  GIST  and  round  cell
tumors,  studies  are  limited  and  treatment  with  HIPEC  is  not
indicated.13
ProcedureA  strict  monitoring  of  the  patient’s  vital  signs  is  required
(temperature  ought  to  be  measured  with  an  esophageal  tem-
perature  probe)  and  a  proper  monitoring  of  diuresis.  After
a  full  resection  of  tumor  implants  and  the  liberation  of
Figure  2  Coliseum  technique,  with  placement  of  inﬂux  and
drainage  tubes  and  temperature  sensors.
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s  retracted,  drainages  are  placed  and  closure  by  planes  is
erformed.13,27
cientiﬁc evidence of the use of CTIP and
IPEC
ver  the  last  two  decades,  combined  treatment  with  CRS
nd  HIPEC  has  modiﬁed  therapeutic  treatment  for  patients
ith  malignancies  on  the  peritoneal  surface,  becoming
he  gold  standard  for  the  management  of  some  of  them.
ccepted  pathologies  for  this  are:  peritoneal  pseudomyx-
ma,  mesothelioma,  colon  cancer,  ovarian  cancer  and
astric  cancer.  The  beneﬁt  of  CTIP  is  shown  in  Table  2. Cardi
t  al.,  recently  published  the  use  of  CRS  and  HIPEC  in  non-
onventional  pathologies  from  a  series  of  253  patients,  28
f  them  with  a  differential  diagnosis  of  sarcoma,  GIST,  and
ifferent  types  of  cancer  such  as  of  the  small  intestine,
ancreas,  breast,  bladder,  lung  and  uterus,  which  showed
 mean  overall  survival  (OS)  of  56  months  and  OS  at  5  years
f  40.3%  with  a  difference  amongst  patients  with  CC0  and
C1  (52.3  versus  25.7%).29 The  two  key  components  in  the
reatment  of  this  pathology  are  CRS  and  CTIP.  A  systematic
eview  of  the  efﬁciency  of  cytoreductive  surgery  and  the
R
i
w
iJ.F.  Castro-Mesta  et  al.
se  of  CTIP  in  peritoneal  pseudomixoma  was  published  by
an  et  al.,  In  this  review,  survival  rate  means  of  51--156
onths  are  shown,  OS  at  1,  2,  3  and  5  years  was  80--100%,
6--96%,  59--96%  and  56--92%  respectively,  with  a  global  mor-
ality  rate  of  0--18%.30 Yonemura  et  al.,  studied  patients  with
astric  cancer  who  underwent  CRS  and  HIPEC,  reporting  sur-
ival  rates  at  5  years  of  61%  compared  to  42%  from  surgery
lone.31 Regarding  colon  cancer,  an  improvement  has  also
een  proven  in  OS  (P  <  0.0001).32 Verwaal  et  al.,  randomized
atients  with  colon  and  rectal  cancer  to  receive  systemic
hemotherapy  with  or  without  palliative  surgery  versus  CRS
ith  HIPEC,  proving  a  beneﬁt  in  mean  survival  rates  in
avor  of  CRS  with  HIPEC.  In  a  follow-up  at  21.6  months,
S  mean  was  22.3  versus  12.6  months  (p  =  0.032),  in  a  sub-
roup  analysis,  researchers  showed  that  patients  with  0--5
ffected  regions  have  better  results  compared  to  patients
ith  6  or  7  affected  regions  (OS  mean  >29  versus  5.4  months
p  <  0.0001}, respectively).  Reported  toxicities  of  3rd  and
th  degree  are  low;  amongst  the  most  common  are  leuco-
enia  (15%),  fever  (6%),  bleeding  (8%),  and  gastrointestinal
stulas  (15%).33 In  2008,  Elias  et  al.,  reported  the  beneﬁt  of
hemo-hyperthermia  with  oxaliplatin  in  patients  with  PC  of
olorectal  origin,  reporting  a survival  rate  of  63  months,  and
 survival  rate  at  5  years  of  51%.34 Hompes  et  al.,  reported
orbidity  and  mortality  rates  with  the  use  of  CRS  and  HIPEC;
ortality  rates  at  30  days  was  0%,  the  rates  of  complications
f  any  degree  was  52%,  anastomosis  leakage  10.4%,  and
leeding  6.3%,  with  an  average  hospital  stay  of  20  days.  With
 follow-up  at  22.7  months,  he  reported  a OS  of  97.9  and
8.7%  at  1  and  2  years,  respectively.  Disease  free  survival
DFS)  of  65.8  and  45.5%  at  1  and  2  years,  respectly.35 Mor-
ality  rate  for  this  treatment  has  been  reported  at  8%.33,36
lehen  et  al.,  conducted  a  multi-institutional,  retrospective
tudy,  which  included  506  patients  with  colon  and  rec-
al  cancer.  Morbidity  rates  were  22.9%  and  mortality  rates
ere  4%,  patients  who  underwent  CRS  reached  OS  means  of
2.4  months  compared  to  8.4  months  for  those  patients  for
hom  CRS  was  not  possible.37 A  meta-analysis  published  by
uo  et  al.,  analyzed  treatment  with  CRS  and  HIPEC  versus
RS  and  intravenous  chemotherapy  in  patients  with  primary
nd  recurrent  epithelial  ovarian  cancer.  In  this  study,  an
mprovement  in  survival  rate  in  favor  of  CRS  and  HIPEC  is
roven.38 Barrios,  et  al.  reported  618  patients  with  CRS  and
IPEC,  561  (91%)  with  CC0-1  and  57  non-optimal  surgeries
9%).  Out  of  the  patients  with  CC0-1,  44%  had  colon  can-
er,  20%  had  peritoneal  pseudomixoma,  15%  had  recurrent
varian  cancer,  5%  had  gastric  cancer,  4%  had  cancer  in  the
ppendix,  3%  had  mesothelioma,  2.3%  had  rectal  cancer,  and
.7%  had  some  other  type  of  cancer.  Survival  rate  mean  was
0.2  months  for  the  group  in  general,  51.2  months  for  the
olon  cancer  group,  45.4  months  for  the  recurrent  ovarian
ancer  group,  29  months  for  the  gastric  cancer  group,  36
onths  for  the  appendix  cancer  (non-pseudomixoma)  group,
6  months  for  the  mesothelioma  group,  and  24  months
or  the  rectal  cancer  group.  Moreover,  the  global  compli-
ation  rate  was  27.5%,  amongst  the  most  frequent  were
entral  line  infections  (3.8%),  non-focal  fevers  (3.8%),  uri-
ary  tract  infections  (2.7%),  and  haemoperitoneums  (2.1%).
e-interventions  were  necessary  in  3.5%  and  the  mortal-
ty  rate  was  0.1%.39 Today,  the  COLOPEC  protocol  is  in  the
orks.  This  protocol  will  evaluate  PC  prevention  with  HIPEC
n  patients  with  high-risk  colon  cancer.27
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Table  2  Scientiﬁc  evidence  of  the  use  of  CTIP  and  HIPEC.
Reference  Base  pathology  Treatment  GSR
Cardi  et  al.29 Sarcomas,  GIST,  cancer  of  the
small  intestine,  pancreas,
breast,  bladder,  lung  and
uterus
CRS  +  HIPEC  Mean,  56  months
At  5  years,  40.3%
CC0  52.3%
CC1  25.7%
Yan et  al.30 Peritoneal  pseudomyxoma  CRS  and  CTIP  Mean,  51--156  months
Yonemura et  al.31 Gastric  cancer  CRS  +  HIPEC  At  5  years,  61%
Verwaal et  al.33 Colon  and  rectal  cancer  CRS  +  HIPEC  vs.  Systemic
chemotherapywith/out
surgery
Mean,  22.3  vs.  12.6
months
Elias et  al.34 Colon  and  rectal  cancer CRS  +  HIPEC Mean,  63  months
Hompes et  al.35 NR  CRS  +  HIPEC At  2  years,  88.7%
Glehen et  al.37 Colon  and  rectal  cancer  CRS  +  HIPEC  vs  no  CRS  Mean,  32.4  vs.  8.4  month
Huo et  al.38 Ovarian  cancer  CRS  +  HIPEC  vs  Systemic
CT  +  surgery
NR
Barrios et  al.39 Colon  cancer,  peritoneal
pseudomyxoma,  recurrent
ovarian  cancer,  stomach,
appendix,  mesothelioma  and
CRS  +  HIPEC  Mean,  60.2  months
C
T
t
Rcolon  cancer
Some  positive  prognosis  indicators  are  CRS,  lymph  node
invasion,  limited  extension  of  PC,  age  under  65  and  the  use
of  adjuvant  chemotherapy.4,37
Quality  of  life  prior  and  subsequent  to  the  CRS  and  HIPEC
procedures  was  assessed  by  a  study.  The  study  showed  a
physical  activity  and  functionality  decrease  in  post-surgery;
however,  the  patients  returned  to  normal  after  3  months  of
treatment.40
Neoadjuvance in CRS with HIPEC
The  optimal  sequence  of  systemic  chemotherapy  in  CRS
radical  treatment  with  HIPEC  is  not  fully  deﬁned.  There
are  few  studies  for  neoadjuvance  and  evidence  is  discord-
ant.  Kuijpers  et  al.,  proved  that  there  is  no  difference  for
OS  and  DFS  between  adjuvance  and  neoadjuvance.41 Some
advantages  that  neoadjuvant  chemotherapy  may  have  are:
undetectable  systemic  disease  treatment,  biological  tumor
behavior  assessment  and  reduction  in  the  tumor  load.  Some
probable  disadvantages  are  the  possible  toxicity  in  post-
surgery,  progression  of  the  disease,  difﬁculty  to  stage  the
disease  and  difﬁculty  to  assess  the  response  to  chemother-
apy.  CRS  and  HIPEC  are  conducted  4  weeks  after  the  last
chemotherapy  dose  and  6  weeks  if  bevacizumab  was  used.37
Conclusion
CRS  and  HIPEC  have  revolutionized  the  treatment  of  patients
with  PC,  reaching  better  results  in  global  survival  and  free-
of-disease  rates.  Patient  selection  is  crucial  and  should  be
conducted  by  a  multidisciplinary  team  in  order  to  achieve
better  results.  It  is  imperative  to  accomplish  full  cytore-
ductive  surgery  in  the  management  of  these  patients,  thus
assuring  the  best  prognosis.  CRS  and  HIPEC  can  be  consid-
ered  the  new  golden  standard  in  the  management  of  patients
with  PC.
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